Bailard, Inc. Intellia Therapeutics, Inc. Transaction History

Bailard, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$132.37 - $176.78 $172,081 - $229,814	-1,300 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$60.88 - $161.91 $73,056 - $194,292	-1,200 Reduced 48.0%	1,300 $210,000
Q1 2021 May 13, 2021	SELL	$46.59 - $83.68 $2.79 Million - $5 Million	-59,800 Reduced 95.99%	2,500 $201,000
Q4 2020 Feb 03, 2021	BUY	$18.83 - $63.53 $41,425 - $139,766	2,200 Added 3.66%	62,300 $3.39 Million
Q2 2020 Aug 12, 2020	BUY	$11.14 - $22.87 $669,514 - $1.37 Million	60,100 New	60,100 $1.26 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $775M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.